SCHEMBL2000543

SCHEMBL2000543

COc1cccc2sc(Cl)nc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 1.00
TDP1 Q9NUW8 4/20 0.65
CYP3A4 P08684 1/20 0.65
KDM4E B2RXH2 6/20 0.59
MAPT P10636 6/20 0.59
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
GAA P10253 2/20 0.59
HPGD P15428 6/20 0.54
TP53 P04637 4/20 0.54
RAB9A P51151 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
NPC1 O15118 3/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
DYRK1A Q13627 1/20 0.54
TSHR P16473 2/20 0.50
PPARG P37231 2/20 0.50
NCOA2 Q15596 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5730270 0.80 ALDH1A1 (0.67) ALDH1A1TDP1CYP3A4KDM4EMAPT
SCHEMBL3123406 0.80 ALDH1A1 (0.67) ALDH1A1TDP1CYP3A4KDM4EMAPT
SCHEMBL3072555 0.80 ALDH1A1 (0.67) ALDH1A1TDP1CYP3A4KDM4EMAPT
Bromide SCHEMBL27302687 0.79 ALDH1A1 (0.65) ALDH1A1TDP1CYP3A4KDM4EMAPT
SCHEMBL624781 0.79 TDP1 (1.00) ALDH1A1TDP1CYP3A4KDM4EMAPT
SCHEMBL2209697 0.79 ALDH1A1 (0.65) ALDH1A1TDP1CYP3A4KDM4EMAPT
SCHEMBL780216 0.79 ALDH1A1 (0.65) ALDH1A1TDP1CYP3A4KDM4EMAPT
SCHEMBL2396893 0.78 ALDH1A1 (0.64) ALDH1A1TDP1CYP3A4KDM4EMAPT
SCHEMBL8358142 0.78 ALDH1A1 (0.62) ALDH1A1TDP1CYP3A4KDM4EMAPT
SCHEMBL6899691 0.77 ALDH1A1 (0.63) ALDH1A1TDP1CYP3A4KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2021-06-24 US disclosed
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2021-06-24 US disclosed
US-10787444-B2 Compounds for the modulation of myc activity SYROS PHARMACEUTICALS, INC. (US) 2020-09-29 US disclosed
US-10787444-B2 Compounds for the modulation of myc activity SYROS PHARMACEUTICALS, INC. (US) 2020-09-29 US disclosed
CN-109963849-A nitrogen-containing heterocyclic compounds as FXR modulators 合帕吉恩治疗公司 2019-07-02 CN disclosed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 US disclosed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 US disclosed
US-5670514-A BENZOQUINOLIN-3-ONE ELI LILLY AND COMPANY (US) 1997-09-23 US disclosed
US-5635197-A BENZO(F)QUINOLIN-3-ONES; ANTICARCINOGENIC AGENTS; BONE DISORDERS ELI LILLY AND COMPANY (US) 1997-06-03 US disclosed
US-5629007-A USING BENZOQUINOLIN-3-ONE DERIVATIVES ELI LILLY AND COMPANY (US) 1997-05-13 US disclosed
US-5622961-A PROSTATE CANCER, SKIN DISORDERS, BALDNESS ELI LILLY AND COMPANY (US) 1997-04-22 US disclosed
US-5622962-A PROSTATE CANCER, SKIN DISORDERS, BALDNESS ELI LILLY AND COMPANY (US) 1997-04-22 US disclosed
US-5578724-A INHIBITORS OF 5-ALPHA-REDUCTASE ELI LILLY AND COMPANY (US) 1996-11-26 US disclosed
WO-1996035422-A1 METHODS FOR INHIBITING BONE LOSS ELI LILLY AND COMPANY (US) 1996-11-14 WO disclosed
EP-0742010-A2 Benzoquinolin-3-ones to inhibit bone loss ELI LILLY AND COMPANY (US) 1996-11-13 EP disclosed
EP-0733365-A2 Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer ELI LILLY AND COMPANY (US) 1996-09-25 EP disclosed
US-5550134-A ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS ELI LILLY AND COMPANY (US) 1996-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 ALDH1A1 2091/4885TDP1 3734/4885CYP3A4 1284/4885
US-20210188833-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 ALDH1A1 2768/4885TDP1 3603/4885CYP3A4 1136/4885
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 ALDH1A1 2768/4885TDP1 3603/4885CYP3A4 1136/4885
US-10787444-B2 Compounds for the modulation of myc activity MYC, MYCBP, MYCBP2 ALDH1A1 2091/4885TDP1 3734/4885CYP3A4 1284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.